Opportunity Information: Apply for RFA DK 13 024
Apply for RFA DK 13 024
- The National Institutes of Health in the food and nutrition health sector is offering a public funding opportunity titled "Harvesting the Neuroimaging Cornucopia for Pancreatic Islet Imaging Reagents for Diabetes Research (DP3)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.286 Discovery and Applied Research for Technological Innovations to Improve Human Health 93.847 Diabetes, Digestive, and Kidney Diseases Extramural Research.
- This funding opportunity was created on Sep 13, 2013 and posted on Sep 13, 2013.
- Applicants must submit their applications by Feb 20, 2014. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- The funding agency has allocated a total of $1,000,000.00 to eligible and selected applicants.
- Each selected applicant is eligible to receive up to $300,000.00 in funding.
- Eligible applicants include: Independent school districts Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education City or township governments State governments Public housing authorities/Indian housing authorities Native American tribal organizations (other than Federally recognized tribal governments) Public and State controlled institutions of higher education Special district governments For profit organizations other than small businesses Small businesses Private institutions of higher education Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Others (see text field entitled Additional Information on Eligibility for clarification) County governments Native American tribal governments (Federally recognized).
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Asian American Native American Pacific Islander Serving Institutions (AANAPISISs) Eligible Agencies of the Federal Government Faith based or Community based Organizations Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Indian/Native American Tribal Governments (Other than Federally Recognized) Non domestic (non U.S.) Entities (Foreign Organizations) Regional Organizations Tribally Controlled Colleges and Universities (TCCUs) U.S. Territory or Possession Non domestic (non U.S.) Entities (Foreign Institutions) are eligible to apply. Non domestic (non U.S.) components of U.S. Organizations are eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The NIH funding opportunity titled "Harvesting the Neuroimaging Cornucopia for Pancreatic Islet Imaging Reagents for Diabetes Research (DP3)" (RFA-DK-13-024) was designed to speed up the discovery of practical imaging tools for studying human pancreatic islet beta cells in living subjects. The central problem it targets is that diabetes develops when beta cells are lost or stop working properly, yet researchers still lack reliable ways to measure beta cell mass and function in people over time. That gap makes it harder to understand how diabetes naturally progresses in humans, to track disease changes in individual patients, or to evaluate whether a therapy is actually preserving or restoring beta cells.
Rather than funding the long, expensive process of inventing entirely new tracers from scratch, this FOA pushes a repurposing approach that leverages what already exists in clinical nuclear medicine. It encourages applicants who have access to major clinical nuclear molecular imaging facilities to screen their existing libraries of PET or SPECT neuroimaging agents, specifically agents that are already approved for use in human subjects research. The idea is straightforward: many beta cells share neurotransmitter-related systems that are also common in the human brain, even though human beta cells differ in important ways from rodent beta cells used in many diabetes models. Because of that overlap with neurobiology, the neuroimaging tracer "toolbox" used in humans may contain compounds that also bind useful targets in human islets. By directly screening these human-ready neuroimaging agents in human subjects and human tissues, researchers may be able to identify promising beta cell imaging candidates faster and more cost-effectively than traditional tracer development pathways.
This FOA uses the DP3 grant mechanism and falls under NIH discretionary grant funding. It is associated with CFDA numbers 93.286 (Discovery and Applied Research for Technological Innovations to Improve Human Health) and 93.847 (Diabetes, Digestive, and Kidney Diseases Extramural Research). The announcement was posted on September 13, 2013, with an original and current closing date of February 20, 2014, and it was archived on March 23, 2014. The estimated total funding level was $1,000,000, and the award ceiling was $300,000. There was no cost sharing or matching requirement, which reduces the need for applicants to bring non-federal funds to the table.
Eligibility for this opportunity was broad and included a wide range of public and private entities. Eligible applicants listed include federal, state, county, city or township governments; special district governments; public and private institutions of higher education; public and Indian housing authorities; nonprofits both with and without 501(c)(3) status; for-profit organizations other than small businesses; and small businesses. The eligibility language also explicitly includes many institution types and communities often called out in NIH programs, such as HBCUs, Hispanic-serving institutions, tribally controlled colleges and universities, Alaska Native and Native Hawaiian-serving institutions, and AANAPISIs, as well as faith-based or community-based organizations. Importantly, non-U.S. entities were also eligible: foreign organizations and foreign institutions could apply, non-domestic components of U.S. organizations were eligible, and foreign components (as defined by NIH policy) were allowed. In practical terms, that means the program was open to international teams as long as they could meet NIH requirements and carry out the proposed human imaging and/or human tissue screening work.
Overall, the FOA is best understood as a targeted push to mine a large existing set of clinically usable neuroimaging tracers and see which ones can be redeployed to visualize or quantify human beta cells, with the long-term goal of making diabetes research and therapeutic evaluation more precise. It reflects a pragmatic strategy: use tools that are already far along the human-safety and human-use pathway, apply them to a major unmet measurement problem in diabetes, and potentially deliver usable beta cell imaging reagents sooner than would be possible through de novo tracer discovery alone.
Frequently Asked Questions (FAQs)
What is the title and identifier of this NIH funding opportunity?
The opportunity is titled "Harvesting the Neuroimaging Cornucopia for Pancreatic Islet Imaging Reagents for Diabetes Research (DP3)" and the FOA number is RFA-DK-13-024.
What problem is this funding opportunity trying to solve?
It targets a major gap in diabetes research: researchers lack reliable, practical ways to measure human pancreatic islet beta cell mass and function in living people over time. Because diabetes develops when beta cells are lost or stop working properly, not being able to measure beta cell changes directly makes it harder to understand disease progression in humans, follow changes in individual patients, and determine whether a therapy is preserving or restoring beta cells.
What is the main scientific goal of the program?
The main goal is to speed up the discovery of practical imaging tools (imaging reagents) for studying human pancreatic islet beta cells in living subjects, enabling better measurement and tracking of beta cell-related outcomes in diabetes research.
What approach does the FOA emphasize: new tracer invention or repurposing existing agents?
This FOA emphasizes repurposing. Instead of funding the long and expensive process of developing entirely new imaging tracers from scratch, it encourages applicants to screen existing clinical nuclear medicine neuroimaging agents that are already approved for use in human subjects research.
What kinds of imaging agents are intended to be screened?
The FOA encourages screening of PET or SPECT neuroimaging agents, specifically agents that are already approved for use in human subjects research.
Why does this program focus on neuroimaging agents for pancreatic islet (beta cell) imaging?
The rationale is that many beta cells share neurotransmitter-related systems that are common in the human brain. Because of this overlap with neurobiology, the existing neuroimaging tracer toolbox used in humans may contain compounds that bind to useful targets in human islets, making them potential beta cell imaging candidates.
Why does the FOA emphasize screening in human subjects and human tissues?
It emphasizes human-based screening because human beta cells differ in important ways from rodent beta cells often used in diabetes models. Screening human-ready neuroimaging agents directly in humans and human tissues is intended to increase relevance to human biology and potentially accelerate identification of usable candidates.
What types of facilities or capabilities does the FOA implicitly prioritize?
It encourages applicants who have access to major clinical nuclear molecular imaging facilities, since the approach relies on screening existing libraries of PET or SPECT neuroimaging agents that are usable in human subjects research.
What is the NIH grant mechanism used for this opportunity?
This FOA uses the DP3 grant mechanism and is described as NIH discretionary grant funding.
What are the CFDA numbers associated with this opportunity?
The FOA is associated with CFDA 93.286 (Discovery and Applied Research for Technological Innovations to Improve Human Health) and 93.847 (Diabetes, Digestive, and Kidney Diseases Extramural Research).
When was the funding opportunity posted, and what were the close dates?
The announcement was posted on September 13, 2013. The original and current closing date listed was February 20, 2014.
Is this opportunity still open for applications?
No. The FOA was archived on March 23, 2014, and the listed closing date was February 20, 2014.
How much total funding was estimated for the program?
The estimated total funding level was $1,000,000.
What was the award ceiling for individual awards?
The award ceiling was $300,000.
Was cost sharing or matching required?
No. The FOA stated there was no cost sharing or matching requirement, meaning applicants were not required to provide non-federal matching funds.
Who was eligible to apply?
Eligibility was broad and included many public and private entity types, including: federal, state, county, city or township governments; special district governments; public and private institutions of higher education; public and Indian housing authorities; nonprofits with or without 501(c)(3) status; for-profit organizations other than small businesses; and small businesses.
Were organizations such as HBCUs, Hispanic-serving institutions, or tribal colleges included in eligibility?
Yes. The eligibility language explicitly included institution types and communities often named in NIH programs, including HBCUs, Hispanic-serving institutions, tribally controlled colleges and universities, Alaska Native and Native Hawaiian-serving institutions, AANAPISIs, and also included faith-based or community-based organizations.
Could foreign (non-U.S.) organizations apply?
Yes. The FOA explicitly allowed foreign organizations and foreign institutions to apply. It also allowed non-domestic components of U.S. organizations and foreign components (as defined by NIH policy).
What does it mean that the program allows foreign components?
Based on the FOA language, it means international participation was permitted: foreign organizations could apply directly, U.S. organizations could include non-domestic components, and foreign components were allowed if they meet NIH policy definitions and requirements while carrying out the proposed work.
What types of research activities does this FOA appear to encourage?
It encourages screening existing libraries of clinically usable PET or SPECT neuroimaging tracers for binding or usefulness in human pancreatic islets/beta cells, using human subjects and/or human tissues to identify promising beta cell imaging candidates.
What is the long-term impact this FOA is aiming for in diabetes research?
The long-term aim is to make diabetes research and therapeutic evaluation more precise by enabling practical imaging tools that can visualize or quantify human beta cells, improving understanding of natural disease progression, patient-level tracking over time, and assessment of whether therapies preserve or restore beta cells.
How is this FOA described in terms of strategy?
It reflects a pragmatic strategy: use tools already far along the human-safety and human-use pathway (human-approved neuroimaging tracers) and apply them to an unmet measurement need in diabetes, potentially delivering usable beta cell imaging reagents sooner than de novo tracer discovery.
Browse more opportunities from the same agency: National Institutes of Health
Browse more opportunities from the same category: Food and Nutrition Health
Next opportunity: Discover Wildlife Refuges Smartphone App
Previous opportunity: Cooperative Agreement between FWS and Partnership for the National Trails System
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA DK 13 024
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (RFA DK 13 024) also looked into and applied for these:
| Funding Opportunity |
|---|
| Human Islet Research Network Coordinating Center (U01) Apply for RFA DK 13 013 Funding Number: RFA DK 13 013 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: $1,000,000 |
| Human Islet Research Network Bioinformatics Center (U01) Apply for RFA DK 13 014 Funding Number: RFA DK 13 014 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: $333,000 |
| Consortium on Targeting And Regeneration (CTAR) HIRN (UC4) Apply for RFA DK 13 015 Funding Number: RFA DK 13 015 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: $600,000 |
| Consortium on Human Islet Biomimetics (CHIB) HIRN (UC4) Apply for RFA DK 13 016 Funding Number: RFA DK 13 016 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: $1,200,000 |
| Consortium on Modeling Autoimmune Interactions (CMAI) HIRN (UC4) Apply for RFA DK 13 017 Funding Number: RFA DK 13 017 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: $600,000 |
| Consortium on Beta cell Death and Survival (CBDS) HIRN (UC4) Apply for RFA DK 13 018 Funding Number: RFA DK 13 018 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: $600,000 |
| Evaluating Natural Experiments in Healthcare to Improve Diabetes Prevention and Treatment (R18) Apply for PAR 13 365 Funding Number: PAR 13 365 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: $500,000 |
| Pragmatic Research in Healthcare Settings to Improve Diabetes Prevention and Care (R18) Apply for PAR 13 366 Funding Number: PAR 13 366 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: $500,000 |
| Planning Grants for Pragmatic Research in Healthcare Settings to Improve Diabetes Prevention and Care (R34) Apply for PAR 13 367 Funding Number: PAR 13 367 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: $150,000 |
| Novel Methods for Detection and Measurement of Organ Fibrosis in Kidney, Bone Marrow and Urological Diseases (U01) Apply for RFA DK 13 026 Funding Number: RFA DK 13 026 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: $250,000 |
| Biomarkers for Diabetes Complications Non Invasive Measures in the Eye (DP3) Apply for RFA DK 13 027 Funding Number: RFA DK 13 027 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: $1,000,000 |
| Limited Competition for the Data Coordinating Center for Type I Diabetes TrialNet (UC4) Apply for RFA DK 13 508 Funding Number: RFA DK 13 508 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: Case Dependent |
| George M. OBrien Urology Cooperative Research Centers Program (U54) Apply for RFA DK 13 020 Funding Number: RFA DK 13 020 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: $1,000,000 |
| Seeding Collaborations for Translational Research to Discover and Develop New Therapies for Diseases and Conditions within NIDDKs Mission (Revisions) (R01) Apply for PAR 14 006 Funding Number: PAR 14 006 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: $75,000 |
| Small Business Innovation Research to Develop New Therapeutics and Monitoring Technologies for Type 1 Diabetes (T1D) Towards an Artificial Pancreas (SBIR) (R43/R44) Apply for RFA DK 13 028 Funding Number: RFA DK 13 028 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: Case Dependent |
| Lead Optimization and Pre Clinical Development of Therapeutic Candidates for Diseases of Interest to NIDDK (STTR (R41/R42)) Apply for PA 14 054 Funding Number: PA 14 054 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: Case Dependent |
| Lead Optimization and Pre Clinical Development of Therapeutic Candidates for Diseases of Interest to the NIDDK (SBIR (R43/R44)) Apply for PA 14 055 Funding Number: PA 14 055 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: Case Dependent |
| Small Business Technology Transfer Research (STTR) to Develop New Diagnostic, Monitoring and Therapeutics Technologies for the Complications of Type 1 Diabetes (T1D) STTR (R41/R42) Apply for PA 14 059 Funding Number: PA 14 059 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: Case Dependent |
| Small Business Innovation Research (SBIR) to Develop New Diagnostic, Monitoring and Therapeutics Technologies for the Complications of Type 1 Diabetes (T1D) (SBIR (R43/R44)) Apply for PA 14 058 Funding Number: PA 14 058 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: Case Dependent |
| Research Using Subjects From Selected Type I Diabetes Clinical Studies (Living Biobank) (DP3) Apply for PAR 14 064 Funding Number: PAR 14 064 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA DK 13 024", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.